StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > StageZero Twitter - FAQ on the Acquisition

<< Previous

Bullboard Posts

Next >>

Comment by RelevantStockon Apr 07, 2021 10:16pm

196 Views

Post# 32954791

RE:RE:RE:RE:RE:RE:RE:StageZero Twitter - FAQ on the Acquisition

You should be more respectful, Clarus is the main architect of the stock price rise before that confusing launch.

Nailbiter1 wrote:
Liked2Think wrote: He should care about not surprising the heck out of our only analyst though.

Maybe if things had gone better he wouldnt had taken 60% of his valuation off the table.

I agree the SP is not the only concern of a ceo but that was ridiculous.

Analysts are a fickle bunch who act and react on the latest news.
AVRT roll out will bring more clarity.
Noel will be like...